SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-201717
Filing Date
2023-08-02
Accepted
2023-08-02 16:10:33
Documents
20
Period of Report
2023-07-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d596862d8k.htm   iXBRL 8-K 33353
2 EX-1.1 d596862dex11.htm EX-1.1 225917
3 EX-5.1 d596862dex51.htm EX-5.1 7764
4 EX-99.1 d596862dex991.htm EX-99.1 10159
5 EX-99.2 d596862dex992.htm EX-99.2 10194
9 GRAPHIC g596862g0802035025565.jpg GRAPHIC 3915
10 GRAPHIC g596862g0802074922131.jpg GRAPHIC 3902
11 GRAPHIC g596862g0802094849345.jpg GRAPHIC 8431
12 GRAPHIC g596862g0802094849472.jpg GRAPHIC 6154
  Complete submission text file 0001193125-23-201717.txt   517814

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tars-20230731.xsd EX-101.SCH 2841
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE tars-20230731_lab.xml EX-101.LAB 18737
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tars-20230731_pre.xml EX-101.PRE 11701
14 EXTRACTED XBRL INSTANCE DOCUMENT d596862d8k_htm.xml XML 3477
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 231135638
SIC: 2836 Biological Products, (No Diagnostic Substances)